Musk threatens Apple with legal action over App Store bias towards OpenAI
Century Therapeutics , Inc. (NASDAQ:IPSC), a biotechnology company specializing in biological products currently trading at $0.68 with a market capitalization of $56.8 million, has been notified by The Nasdaq Stock Market LLC of a potential delisting due to its share price falling below the required minimum. According to InvestingPro data, the stock has declined over 80% in the past year, currently trading near its 52-week low of $0.67. The notification, received on February 26, 2025, indicated that for 31 consecutive business days, the closing bid price of Century’s common stock was under the $1.00 threshold mandated by Nasdaq’s Listing Rule 5450(a)(1).
The notice from Nasdaq is not an immediate delisting action but serves as a deficiency warning. Century’s stock will continue to trade on The Nasdaq Global Select Market as the company addresses the issue. InvestingPro analysis indicates the company maintains a WEAK financial health score, with particularly concerning metrics in profitability and price momentum. The company has been granted a 180-day period, until August 25, 2025, to regain compliance. To meet Nasdaq’s standards, the company’s closing bid price must remain at or above $1.00 per share for a minimum of 10 consecutive business days.
Should Century fail to comply within the allotted timeframe, it has the option to transfer its listing to the Nasdaq Capital Market, assuming it meets all other listing requirements except for the bid price. Upon transferring, Century would receive an additional 180-day period to meet the bid price requirement as per Nasdaq Listing Rule 5810(c)(3)(A)(ii).
Century Therapeutics has expressed its intent to closely monitor its share price and explore all possible avenues to regain compliance with Nasdaq’s listing requirements. Investors should note that the company’s next earnings report is scheduled for March 13, 2025, with analyst price targets ranging from $4 to $13, suggesting potential upside if the company can execute its turnaround strategy. The company’s management is considering various strategies, but there is no certainty that compliance will be achieved within the compliance period or subsequent extension.
This development includes forward-looking statements regarding Century’s intentions and potential actions to address the non-compliance with Nasdaq’s listing rule. These statements are based on current expectations and projections about future events and are subject to risks, uncertainties, and changes in circumstances that may cause actual outcomes to differ materially.
The information in this article is based on a press release statement from Century Therapeutics and reflects the company’s current situation as of February 28, 2025, without any additional commentary or speculation on future outcomes. For deeper insights into Century Therapeutics’ financial health, valuation metrics, and exclusive ProTips, consider subscribing to InvestingPro.
In other recent news, Century Therapeutics has announced a partnership with Friedrich-Alexander University Erlangen-Nürnberg for a Phase 1/2 trial of its cell therapy CNTY-101, targeting B-cell mediated autoimmune diseases. This trial will assess the safety and efficacy of the therapy, which aims to treat conditions like systemic lupus erythematosus and lupus nephritis. Piper Sandler has maintained an Overweight rating for Century Therapeutics, despite reducing its price target to $4, reflecting the ongoing progress in the Phase I CALiPSO-1 study. In a separate development, Century Therapeutics and Bristol-Myers Squibb (NYSE:BMY) have mutually agreed to terminate their collaboration on therapies for hematologic malignancies, effective March 2025. This decision follows Bristol-Myers Squibb’s portfolio prioritization, though Century remains optimistic about its scientific advancements. Clear Street has initiated coverage on Century Therapeutics with a Buy rating and a $9 price target, emphasizing the potential of the company’s iPSC platform. The firm believes that Century’s stock presents an attractive risk-reward balance due to its innovative cell therapy technology. Century ended the third quarter of 2024 with a robust cash position of $245 million, supporting its ongoing clinical trials and strategic reviews.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.